Clinical trial
Protocol H8 for a Prospective Controlled Trial in Clinical Stage I-II Supradiaphragmatic Hodgkin's Disease. Evaluation of Treatment Efficacy and (Long Term) Toxicity in Three Different Prognostic Subgroups [H8 Trial]
NCT00379041 is registered in ClinicalTrials.gov with European Organisation for Research and Treatment of Cancer - EORTC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Protocol H8 for a Prospective Controlled Trial in Clinical Stage I-II Supradiaphragmatic Hodgkin's Disease. Evaluation of Treatment Efficacy and (Long Term) Toxicity in Three Different Prognostic Subgroups [H8 Trial]
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- September 1, 1993
- Completion date
- Not reported
- Enrollment
- 1,158 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.